VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ALLThe Allstate Corporation
$239.61$61.7B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksALLFinancials

The Allstate Corporation (ALL) Financials

30Y historyFree accessUpdated daily

Operating income surged to $3.2 billion in 2026Q1, reflecting a significant recovery from the 2025Q1 loss ratio peak of 81.4%.

ALL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue67.14B66.46B63.52B56.59B50.62B48.68B41.69B41.1B39.81B39.41B37.4B35.65B35.24B34.51B33.31B32.65B31.4B32.01B29.39B36.77B35.8B35.38B33.94B32.15B29.58B28.86B29.13B26.96B25.88B24.95B24.3B
Revenue Growth %3.73%4.64%12.24%11.8%3.98%16.76%1.43%3.24%1.04%5.37%4.9%1.17%2.12%3.58%2.02%3.99%-1.91%8.91%-20.06%2.72%1.17%4.26%5.56%8.69%2.47%-0.92%8.07%4.17%3.73%2.67%5.61%
Medical Costs & Claims40.4B44.37B49.02B49.42B44.94B36.65B28.66B29.96B30.63B29.24B29.35B27.96B26.25B25.11B25.5B27.54B26.38B3.74B4.02B4.27B4.18B4.02B3.62B3.7B3.53B3.4B3.19B2.58B2.42B2.42B2.38B
Medical Cost Ratio %60.17%66.77%77.17%87.33%88.78%75.28%68.75%72.9%76.92%74.21%78.49%78.43%74.48%72.76%76.55%84.33%84.01%11.69%13.69%11.61%11.67%11.36%10.66%11.5%11.95%11.79%10.95%9.56%9.33%9.68%9.8%
Gross Profit26.74B22.09B14.5B7.17B5.68B12.03B13.03B11.14B9.19B10.16B8.04B7.69B8.99B9.4B7.81B5.12B5.02B28.27B25.37B32.5B31.62B31.36B30.32B28.45B26.05B25.46B25.94B24.38B23.46B22.53B21.92B
Gross Margin %39.83%33.23%22.83%12.67%11.22%24.72%31.25%27.1%23.08%25.79%21.51%21.57%25.52%27.24%23.45%15.67%15.99%88.31%86.31%88.39%88.33%88.64%89.34%88.5%88.05%88.21%89.05%90.44%90.67%90.32%90.2%
Gross Profit Growth %-52.32%102.18%26.33%-52.82%-7.64%16.94%21.25%-9.59%26.33%4.6%-14.47%-4.33%20.3%52.72%1.91%-82.24%11.43%-21.93%2.79%0.8%3.46%6.55%9.24%2.29%-1.86%6.41%3.91%4.13%2.81%5.05%
Operating Expenses11.1B8.93B8.74B7.52B7.51B5.57B6.22B5.7B6.56B5.61B5.29B4.41B4.76B6B4.51B4.16B3.92B27.02B28.4B25.85B24.44B29.28B25.73B24.88B24.5B24.11B22.9B20.47B18.72B18.1B19.25B
OpEx / Revenue %16.53%13.44%13.76%13.29%14.83%11.43%14.93%13.86%16.48%14.25%14.15%12.37%13.5%17.4%13.53%12.73%12.48%84.41%96.6%70.29%68.27%82.74%75.82%77.39%82.85%83.54%78.59%75.94%72.33%72.55%79.22%
Depreciation & Amortization397M482M555M704M847M1.09B686M647M511M483M382M371M366M368M388M252M94M-91M-376M-257M-188M-67M-4M-3M-62M-106M-47M-17M-22M-22M-19M
Combined Ratio %76.7%80.2%90.93%100.61%103.62%86.72%83.69%86.76%93.4%88.46%92.64%90.79%87.98%90.16%90.08%97.06%96.5%96.1%110.29%81.91%79.95%94.1%86.49%88.89%94.79%95.33%89.54%85.51%81.66%82.23%89.02%
Operating Income15.64B13.16B5.76B-348M-1.83B6.47B6.8B5.44B2.63B4.55B2.75B3.28B4.24B3.4B3.31B959M1.1B1.25B-3.02B6.65B7.18B2.09B4.59B3.57B1.54B1.35B3.05B3.91B4.75B4.43B2.67B
Operating Margin %23.3%19.8%9.07%-0.61%-3.62%13.28%16.31%13.24%6.6%11.54%7.36%9.21%12.02%9.84%9.92%2.94%3.5%3.9%-10.29%18.09%20.05%5.9%13.51%11.11%5.21%4.67%10.46%14.49%18.34%17.77%10.98%
Operating Income Growth %-128.36%1755.46%80.98%-128.3%-4.94%24.97%107.12%-42.23%65.18%-16.09%-22.52%24.73%2.72%244.73%-12.82%-11.86%141.26%-145.47%-7.31%243.77%-54.47%28.42%131.88%14.24%-55.76%-22.01%-17.66%7.01%66.13%-87.16%
EBITDA16.04B13.64B6.32B356M-983M7.55B7.49B6.09B3.14B5.03B3.14B3.65B4.6B3.76B3.69B1.21B1.19B1.16B-3.4B6.4B6.99B2.02B4.58B3.57B1.48B1.24B3B3.89B4.72B4.41B2.65B
EBITDA Margin %23.89%20.52%9.94%0.63%-1.94%15.51%17.96%14.82%7.88%12.77%8.39%10.25%13.06%10.91%11.09%3.71%3.8%3.61%-11.57%17.4%19.53%5.71%13.5%11.1%5%4.3%10.3%14.43%18.25%17.68%10.91%
Interest Expense397M399M400M379M335M330M318M327M332M335M295M292M322M367M373M367M367M392M351M333M357M330M308M275M278M129M229M129M118M100M95M
Non-Operating Income-326M-399M-400M-379M-335M-330M-318M-327M-332M-335M-295M-292M-322M-367M-373M-367M-367M-392M-351M-333M-357M-330M-308M-275M-278M-185M-229M-129M-118M-100M-95M
Pretax Income15.54B13.16B5.76B-348M-1.83B6.47B6.8B5.44B2.63B4.55B2.75B3.28B4.24B3.4B3.31B959M1.1B1.25B-3.02B6.65B7.18B2.09B4.59B3.57B1.54B1.28B3.05B3.91B4.75B4.43B2.67B
Pretax Margin %23.15%19.8%9.07%-0.61%-3.62%13.28%16.31%13.24%6.6%11.54%7.36%9.21%12.02%9.84%9.92%2.94%3.5%3.9%-10.29%18.09%20.05%5.9%13.51%11.11%5.21%4.45%10.46%14.49%18.34%17.77%10.98%
Income Tax3.42B2.89B1.16B-135M-488M1.29B1.37B1.12B468M995M877M1.11B1.39B1.12B1B172M189M394M-1.35B2.02B2.19B323M1.23B846M65M73M795M1.15B1.42B1.32B619M
Effective Tax Rate %21.98%21.97%20.17%38.79%26.67%19.98%20.19%20.5%17.81%21.87%31.84%33.85%32.72%32.86%30.25%17.94%17.18%31.57%44.5%30.32%30.44%15.47%26.82%23.69%4.22%5.68%26.09%29.38%29.97%29.86%23.19%
Net Income12.14B10.28B4.67B-188M-1.29B1.61B5.58B4.85B2.16B3.55B1.88B2.17B2.85B2.28B2.31B787M911M854M-1.68B4.64B4.99B1.76B3.18B2.71B1.13B1.16B2.21B2.72B3.29B3.1B2.08B
Net Margin %18.09%15.47%7.35%-0.33%-2.55%3.32%13.37%11.79%5.43%9.02%5.02%6.09%8.09%6.61%6.92%2.41%2.9%2.67%-5.71%12.61%13.95%4.99%9.37%8.41%3.83%4.01%7.59%10.09%12.73%12.45%8.54%
Net Income Growth %200.32%120.31%2582.45%85.42%-179.86%-71.05%15.04%124.4%-39.22%89.34%-13.54%-23.82%25%-1.13%193.01%-13.61%6.67%150.86%-136.22%-7.15%182.89%-44.51%17.6%138.54%-2.07%-47.63%-18.71%-17.43%6.09%49.64%8.98%
EPS (Diluted)46.2538.1916.99-1.20-5.0317.2517.3114.036.129.354.675.056.274.814.681.501.681.58-3.077.777.842.644.543.831.601.602.953.383.943.562.32
EPS Growth %209.56%124.78%1515.83%76.14%-129.16%-0.35%23.38%129.25%-34.55%100.21%-7.52%-19.46%30.35%2.78%212%-10.71%6.33%151.47%-139.51%-0.89%196.97%-41.85%18.54%139.38%0%-45.76%-12.72%-14.21%10.67%53.45%9.43%
EPS (Basic)-38.6817.22-1.20-5.0317.5017.5314.256.219.504.725.126.374.874.711.511.691.58-3.077.837.892.674.573.851.601.612.973.403.963.582.33
Diluted Shares Outstanding262.6M264.7M267.8M262.5M271.2M299.1M315.5M333.5M353.2M367.8M377.3M406.8M438.2M470.3M493M523.1M542.5M540.9M546.1M596.7M637.2M667.3M700.3M706.2M709.9M723.3M748.7M803.8M836.6M873M897.4M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrong
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Catastrophe loss volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Premium Growth Normalizing After Surge

According to the provided quarterly data, Allstate's revenue growth has decelerated from a peak of 15.3% in 2024Q3 to 4.2% by 2026Q1, suggesting that aggressive rate-taking actions are beginning to encounter resistance in a highly competitive personal lines insurance market environment.

The transition from double-digit growth to mid-single digits indicates that the initial benefit of rapid rate increases is fading as the company balances pricing power against customer retention. Investors should monitor whether this deceleration reflects a strategic pivot toward underwriting discipline or a loss of market share to more agile digital-first competitors.

Underwriting Profitability Shows Significant Recovery

As reported in financial statements, the combined ratio improved dramatically from a strained 97.2% in 2024Q2 to a robust 81.1% in 2026Q1, reflecting a successful effort to align premium pricing with the underlying inflationary pressures impacting claims and adjustment expenses.

This sharp contraction in the combined ratio suggests that the company has effectively navigated the peak of the recent inflationary cycle. The improvement appears to be driven by both disciplined rate adjustments and a potential reduction in the frequency of severe catastrophe events compared to the prior year.

2025Q1 Marks Critical Margin Trough

Based on the company's reported figures, 2025Q1 represented a pivotal inflection point where the loss ratio peaked at 81.4%, subsequently triggering a rapid recovery in operating income from $719 million to $3.2 billion by the first quarter of 2026.

This period serves as a clear case study in the lag between inflationary cost spikes and the realization of earned premium rate increases. The subsequent margin expansion suggests that the company's pricing models have successfully caught up to the cost environment, though the sustainability of these margins remains contingent on future loss trends.

Reserve Adequacy and Litigation Tailwinds

While the reported combined ratio suggests strong underwriting performance, the persistent threat of social inflation and rising litigation costs, as noted in industry-wide trends, warrants further investigation into whether current reserve levels are sufficient to cover long-tail claims that may emerge in future periods.

The rapid improvement in recent quarters could potentially mask underlying volatility if prior-year reserve releases are being utilized to bolster current earnings. Analysts should remain cautious regarding the potential for future reserve strengthening, which could negatively impact net income if the current litigation environment continues to deteriorate.

ALL — Frequently Asked Questions

Quick answers to the most common questions about buying ALL stock.

What was The Allstate Corporation's (ALL) revenue in 2025?

For fiscal year 2025, The Allstate Corporation (ALL) reported total revenue of $66.46B. This represents a 173.5% increase compared to $24.30B in 1996.

Is The Allstate Corporation (ALL) profitable?

The Allstate Corporation (ALL) is profitable, generating $10.28B in net income for the fiscal year ending 2025 with a net profit margin of 15.5%.

What is The Allstate Corporation's operating profit margin?

The Allstate Corporation (ALL) reported an operating income of $13.16B, resulting in an operating profit margin of 19.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is The Allstate Corporation's gross profit and gross margin?

The Allstate Corporation (ALL) generated $22.09B in gross profit for the year, representing a gross profit margin of 33.2%. This demonstrates the company's core pricing power and production efficiency.